🇺🇸 FDA
Patent

US 8685932

Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 8685932 (Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases) held by OPTION PHARMACEUTICALS, LLC expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OPTION PHARMACEUTICALS, LLC
Grant date
Tue Apr 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/505, A61K39/3955, A61P, A61P29/00